Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Art Pappas
AddedMar 31, 2024
UpdatedMay 31, 2026
Art Pappas

Art Pappas

Board Member, National Venture Capital Association

CrunchbaseLinkedIn

Art Pappas's Career

National Venture Capital Association
National Venture Capital Association

Washington, D.C., DC, US

Board Member· Board
North Carolina Biotechnology Center
North Carolina Biotechnology Center

Triangle (historical), NC, US

Board Member· Board
Pappas Capital
Pappas Capital

Durham, NC, US

CEO· C-Suite · Management
Syndax Pharmaceuticals
Syndax Pharmaceuticals

Waltham, MA, US

Board Member· Board
CeNeRx Biopharma
CeNeRx Biopharma

Cary, NC, US

Board Member· Board
BrainCells
BrainCells

San Diego, CA, US

Board Member· Board
OrphoMed
OrphoMed

San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Art Pappas's Career

National Venture Capital Association
National Venture Capital Association
NonprofitNonprofit721982Washington, D.C., DC, US
Board Member· Board

Recent news

a16z spends $1.49M in Washington lobbying, while rivals mostly sit outTechCrunch · 2025

Leadership at National Venture Capital Association

Jan GarfinkleJan GarfinkleBoard Member
Nick WashburnNick WashburnBoard Member
Vic ParkerVic ParkerBoard Member
Rob KettersonRob KettersonBoard Member
Jennifer TeganJennifer TeganBoard Member
Niten MalhanNiten MalhanBoard Member

Similar to National Venture Capital Association

Venture for AmericaVenture for AmericaNew York City, NY, USest. 2011Venture for AmericaNew York City, NY, US · est. 2011

Venture for America: A non-profit fostering economic growth in US cities through entrepreneurship training.

Nonprofit405
VentureWellVentureWellHadley, MA, USTrainingest. 1995VentureWellHadley, MA, US · est. 1995

VentureWell: Funding, training, and catalyzing student-led ventures for social and environmental impact.

Nonprofit143
Activation CapitalActivation CapitalRichmond, VA, USInnovation Programsest. 1993Activation CapitalRichmond, VA, US · est. 1993

Empowering innovation and talent in Richmond's ecosystem.

Nonprofit · $15M3
Western New York Venture AssociationWestern New York Venture AssociationBuffalo, NY, USBusiness, Investmentest. 1989Western New York Venture AssociationBuffalo, NY, US · est. 1989

WNY Venture Association: Promoting business and investment opportunities in Western New York.

Nonprofit1
North Carolina Biotechnology Center
North Carolina Biotechnology Center
Series B$30.4M1161984Triangle (historical), NC, US
Board Member· Board

Leadership at North Carolina Biotechnology Center

Ben YerxaBen YerxaBoard Member
James HuntJames HuntFounder
Doug EdgetonDoug EdgetonCEO
Pappas Capital
Pappas Capital
Investment FirmInvestment Firm311994Durham, NC, US
CEO· C-Suite · Management

Similar to Pappas Capital

A. M. Pappas & AssociatesA. M. Pappas & AssociatesDurham, NC, USest. 1994A. M. Pappas & AssociatesDurham, NC, US · est. 1994

M. Pappas & Associates: A Durham-based venture capital firm managing $350M, investing in life sciences, and fostering entrepreneurial growth.

Investment Firm30
MPM CapitalMPM CapitalBoston, MA, USest. 1996MPM CapitalBoston, MA, US · est. 1996

MPM Capital L.P. is a US-based healthcare investment firm, specializing in venture capital for therapeutic areas.

Investment Firm30
Epidarex CapitalEpidarex CapitalBethesda, MD, USest. 2010Epidarex CapitalBethesda, MD, US · est. 2010

Epidarex Capital: A transatlantic venture capital firm investing in early-stage life science opportunities.

Investment Firm16
Ra Capital ManagementRa Capital ManagementBoston, MA, USest. 2001Ra Capital ManagementBoston, MA, US · est. 2001

RA Capital Management: Boston-based investment advisor specializing in life-sciences and drug development.

Investment Firm183
Syndax Pharmaceuticals
Syndax Pharmaceuticals
Public$803.6M1072005Waltham, MA, US
Board Member· Board

Leadership at Syndax Pharmaceuticals

Dennis PodlesakDennis PodlesakBoard Member
Eckard WeberEckard WeberBoard Member
Michael A. MetzgerMichael A. MetzgerBoard Member
Pierre LegaultPierre LegaultBoard Member
Jennifer JarrettJennifer JarrettBoard Member
Dr. Ronald M. Evans Ph.D.Dr. Ronald M. Evans Ph.D.Board Member
CeNeRx Biopharma
CeNeRx Biopharma
Series A$59.3M62005Cary, NC, US
Board Member· Board

Leadership at CeNeRx Biopharma

Mark BaricMark BaricBoard Member
Barry BrandBarry BrandBoard Member
BrainCells
BrainCells
Seed$73.7M302003San Diego, CA, US
Board Member· Board

Leadership at BrainCells

Eric KandelEric KandelCo-Founder
Susan DubeSusan DubeCo-Founder
Charles W Newhall III \"Chuck\"Charles W Newhall III \"Chuck\"Board Member
Dr Fred H GageDr Fred H GageBoard Member
Fred GageFred GageCo-Founder

Similar to BrainCells

GliacureGliacureBoston, MA, USTherapeuticsest. 2011GliacureBoston, MA, US · est. 2011

Boston-based GliaCure develops innovative therapies for neurological and neuropsychiatric disorders.

Seed · $11.1M8
Cell Reprogramming & TherapeuticsCell Reprogramming & TherapeuticsWauwatosa, WI, USTherapeuticsest. 2014Cell Reprogramming & TherapeuticsWauwatosa, WI, US · est. 2014

Cell Reprogramming & Therapeutics: Pioneering cell reprogramming tech for CNS disease treatment since 2013.

Angel · $370k5
Cellular ApproachesCellular ApproachesLos Angeles, CA, USCell Therapiesest. 2016Cellular ApproachesLos Angeles, CA, US · est. 2016

Cellular Approaches: Innovating in innate immunity biotech for unmet medical needs.

Seed · $2.6M5
Cerebral TherapeuticsCerebral TherapeuticsAurora, CO, USPharmaceuticalsest. 2010Cerebral TherapeuticsAurora, CO, US · est. 2010

Cerebral Therapeutics: A clinical-stage pharma company specializing in neurological diseases, primarily epilepsy.

Series C · $85.8M26
OrphoMed
OrphoMed
Series A$41.8M402015San Francisco, CA, US
Board Member· Board

Leadership at OrphoMed

Frank TortiFrank TortiBoard Member
Nikhilesh SinghNikhilesh SinghBoard Member
Pankaj Jay PasrichaPankaj Jay PasrichaCo-Founder
Gary M PhillipsGary M PhillipsCEO
Frank SteinbergFrank SteinbergCo-Founder
Michael MartinMichael MartinBoard Member

Art Pappas's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLee Sirg-OoLee Sirg-OoCEO · DunamuChi-hyung SongChi-hyung SongBoard Member · DunamuIn-hyuk ChoiIn-hyuk ChoiCEO · Naver FinancialWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Art Pappas

Harry PappHarry PappBoard Member · Public Safety Personnel Retirement SystemFrank ChiuFrank ChiuCo-Founder · P2P CapitalSamer AbousalbiSamer AbousalbiCEO · CapparsaRafi AmjadRafi AmjadFounder · PapafundSean E. RogersSean E. RogersCEO · Pasaca CapitalAngelos PapadimitriouAngelos PapadimitriouBoard Member · Athena Ventures